- Poster Presentations to Explore Potential of Augmenting Resokine Pathway in Severe, Rare Pulmonary Diseases with an Immune or Fibrotic Component - - Conference Call and Webcast Featuring Guest Speaker Dr. Steven Nathan on May 23, 2017 at 8:30 am ET - SAN DIEGO , May 15, 2017 (GLOBE NEWSWIRE) --

  – Announced Promising Top-Line Results from Resolaris TM  Phase 1b/2 Trial in Early Onset FSHD – – Preclinical Data from Stalaris TM Program to be Presented at American Thoracic Society International Conference in May 2017 – – aTyr Pharma to Host Educational Webinar on Stalaris Program for the

- Resolaris Demonstrated Favorable Safety Profile and Promising Signals of Clinical Activity - - Resolaris has FDA Fast Track and Orphan Drug Designation for Limb Girdle Muscular Dystrophy 2B (LGMD2B) and Facioscapulohumeral Muscular Dystrophy (FSHD) - SAN DIEGO – April 24, 2017 – aTyr Pharma, Inc.

- 63% of Patients Observed Increased Muscle Strength - - Resolaris Demonstrated a Generally Well-Tolerated Safety Profile in Younger Patient Population - SAN DIEGO – April 24, 2017 – aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of

SAN DIEGO – April 10, 2017 – aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of Physiocrine-based therapeutics to address severe, rare diseases, today announced the appointment of Timothy P. Coughlin to its board of directors. Mr.

SAN DIEGO, April 3, 2017 / PRNewswire / -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of Physiocrine-based therapeutics to address severe, rare diseases, today announced the appointment of Mr. Jeffrey S.

SAN DIEGO – Mar. 29, 2017 – aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of Physiocrine-based therapeutics to address severe, rare diseases, today announced the Company’s presentation at the Needham and Company 16 th  Annual Healthcare

- Resolaris™, in multiple rare myopathy indications in four clinical trials in 2016, demonstrated signals of clinical activity and a favorable safety profile - - Advancing second program, Stalaris™, for rare lung indications into a first in human clinical trial in 2H17 - - Closing in on third

- Estate Covers over 175 Patents for Physiocrine Biology, a New Class of Potential Targets and Therapeutics - - Over 100 Patents Issued or Allowed in the Past 12 Months - SAN DIEGO , March 15, 2017 / PRNewswire / -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the

SAN DIEGO , March 3, 2017 / PRNewswire / -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of Physiocrine-based therapeutics to address severe, rare diseases, today announced that the European Medicines Agency (EMA) has granted orphan drug